The role of illness perception and behaviour in the treatment of adolescents with multisystem functional somatic disorders: a post hoc mediation analysis of the AHEAD trial.

Cogn Behav TherJun 26, 2025 (epub)
Clinical ResearchPsychiatry

Karen H Kallesøe, Eva Ørnbøl, Kaare Bro Wellnitz et al.

✦ AI-curated · Sources linked

In 30 seconds

This post-hoc mediation analysis of the randomised AHEAD trial examined whether illness perceptions, illness behaviour, and psychological inflexibility mediated changes in self-perceived physical health among 91 adolescents aged 15–19 years with multisystem functional somatic disorders lasting at least 1 year. Adolescents received group-based Acceptance and Commitment Therapy or Enhanced Usual Care. At 8 months, improvements in negative illness perceptions and experiential avoidance mediated the effect of AHEAD on physical health. Mediation appeared greater at higher baseline levels of these factors, but moderation effects were not statistically significant.

Key findings

  • Improvements in negative illness perceptions mediated AHEAD’s effect on self-perceived physical health at 8 months.
  • Reduced experiential avoidance also mediated the effect on physical health.
  • Mediation effects increased with higher baseline levels, but moderation effects were non-significant.

Why it matters

The findings suggest that changes in how adolescents interpret and respond to illness may help explain improvements in perceived physical health during psychological treatment for multisystem functional somatic disorders. These potential mechanisms can inform evaluation of treatment programmes, while the non-significant moderation results do not establish that baseline levels identify who benefits most.

What to keep in mind

This was a post-hoc mediation analysis of trial data, so the proposed mechanisms are not definitive. The analysis included 91 adolescents and assessed outcomes 3 months after treatment ended.

Source

Published in Cogn Behav Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.